Dosing & Uses
Dosage Forms & Strengths
Treatment of acute gout flares (Colcrys): 1.2 mg PO at first sign of flare, then 0.6 mg 1 hr later; not to exceed 1.8 mg in 1-hr period
Prophylaxis (Colcrys, Mitigare): 0.6 mg PO once daily or q12hr; not to exceed 1.2 mg/day; after gout flare, wait 12 hr to continue prophylaxis
Familial Mediterranean Fever
Colcrys: 1.2-2.4 mg/day PO in single daily dose or divided q12hr; increased in 0.3 mg/day increments as necessary to control disease; decreased in 0.3 mg/day increments if intolerable side effects develop; not to exceed 2.4 mg/day
Renal impairment (gout)
- Mild (CrCl 50-80 mL/min) and moderate (CrCl 30-50 mL/min): Dosage adjustment not necessary; monitor patients for adverse effects
- Severe (CrCl <30 mL/min): Dosage adjustment not necessary; do not repeat more frequently than every 2 weeks
- Hemodialysis: 0.6 mg once; do not repeat more frequently than every 2 weeks
Renal impairment (familial Mediterranean fever)
- Mild (CrCl 50-80 mL/min) and moderate (CrCl 30-50 mL/min): Monitor patients for adverse effects; dosage adjustment may be required
- Severe (CrCl <30 mL/min): 0.3 mg/day initially; dosage increases should be done with adequate monitoring for adverse effects
- Hemodialysis: 0.3 mg PO once; dosage increases should be done with adequate monitoring for adverse effects
Hepatic impairment (gout)
- Mild to moderate: Dosage adjustment not necessary; monitor patients for adverse effects
- Severe: Dosage adjustment not necessary; do not repeat more frequently than every 2 weeks; consider alternative therapy if repeated courses are required
Hepatic impairment (familial Mediterranean fever)
- Mild to moderate: Monitor patients for adverse effects
- Severe: Consider dosage reduction; do not repeat more frequently than every 2 weeks
Strong CYP3A4 inhibitors
- Treatment of acute gout flares: 0.6 mg, then 0.3 mg 1 hour later; to be repeated no earlier than 3 days later
- Prophylaxis of acute gout flares: If the original colchicine regimen was 0.6 mg BID, decrease dose to 0.3 mg qDay; if the original colchicine regimen was 0.6 mg qDay, decrease dose to 0.3 mg once every other day
- Familial Mediterranean fever (FMF): Not to exceed 0.6 mg/day; 0.6 mg can be given as 0.3 mg q12hr
Moderate CYP3A4 inhibitors
- Gout: 1.2 mg PO once; to be repeated no earlier than 3 days later
- FMF: Not to exceed 1.2 mg/day; 0.6 mg can be given as 0.6 mg q12hr
- Gout: 0.6 mg PO once; to be repeated no earlier than 3 days later
- FMF: Not to exceed 0.6 mg/day; 0.6 mg can be given as 0.3 mg q12hr
Dosing regimens must be individualized to indication
Administered PO, without regard to meals
Post-STEMI Pericarditis (Off-label)
Treatment of pericarditis after ST-elevation myocardial infarction (STEMI)
0.6 mg PO q12hr
Behcet Syndrome (Orphan)
- AR Scientific, Inc, 1100 Orthodox Street, Philadelphia, PA 19124
Dosage Forms & Strengths
- Not recommended
- Treatment of acute gout flares (Colcrys): 1.2 mg PO at first sign of flare, then 0.6 mg 1 hr later; not to exceed 1.8 mg in 1-hr period
- Prophylaxis (Colcrys, Mitigare): 0.6 mg PO once daily or q12hr; not to exceed 1.2 mg/day; after gout flare, wait 12 hr to continue prophylaxis
Familial Mediterranean Fever
<4 years: Safety and efficacy not established
4-6 years: 0.3-1.8 mg/day PO in single daily dose or divided q12hr
6-12 years: 0.9-1.8 mg/day PO in single daily dose or divided q12hr
>12 years: 1.2-2.4 mg/day PO in single daily dose or divided q12hr
- Increased or decreased in 0.3 mg/day increments as necessary; not to exceed maximum recommended daily dose
Serious - Use Alternative
Significant - Monitor Closely
Gastrointestinal (GI) effects (eg, diarrhea, nausea, cramping, abdominal pain, vomiting) (26-77%)
Pharyngolaryngeal pain (2-3%)
Disseminated intravascular coagulation
Cellular injury (eg, to kidney, vasculature, liver, central nervous system)
Neurologic: Sensory motor neuropathy
Dermatologic: Alopecia, purpura, maculopapular rash, rash
GI: Lactose intolerance, abdominal cramping, abdominal pain, vomiting, diarrhea, nausea
Hematologic: Thrombocytopenia, leukopenia, granulocytopenia, pancytopenia, aplastic anemia
Hepatobiliary: Elevated liver transaminases
Musculoskeletal: Myotonia, muscle weakness, myopathy, elevated creatine phosphokinase, muscle pain, rhabdomyolysis
Reproductive: Azoospermia, oligospermia
Coadministration with P-gp or strong CY3A4 inhibitors in patients with hepatic or renal impairment; life-threatening and fatal colchicine toxicity has been reported with therapeutic dosages
Long term use is established for FMF, but safety and efficacy of repeat treatment in gout flares has not been evaluated
Not to be used to treat pain from other causes; drug is not analgesic
Must be kept out of reach of children; fatal overdoses have been reported
Blood dyscrasias (eg, leukopenia, myelosuppression, thrombocytopenia, pancytopenia, granulocytopenia, aplastic anemia) have been reported at therapeutic dosages
Coadministration with P-gp and strong CYP3A4 inhibitors may warrant dosage reduction or interruption of therapy
Rhabdomyolysis and neuromuscular toxicity have been reported with long-term treatment at therapeutic dosages; increased risk with renal dysfunction, elderly patients, concomitant therapy with myotoxic drugs; symptoms generally resolve within 1 week to few months upon discontinuance
Acute gout: Dosages >1.8 mg/day provide no additional efficacy
Dose reduction recommended in patients who develop gastrointestinal symptoms including anorexia, diarrhea, vomiting, or nausea due to the therapy
Clearance is decreased in renal and hepatic impairment; monitor for toxicity and adjust dose if necessary
Use with caution in the elderly; consider adjusting dose
Pregnancy & Lactation
Pregnancy category: C
Lactation: Drug enters breast milk; use with caution (American Academy of Pediatrics Committee states that drug is "compatible" with nursing)
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Gout: Disruption of cytoskeletal functions through inhibition of β-tubulin polymerization into microtubules; this prevents activation, degranulation, and migration of neutrophils thought to mediate some gout symptoms
FMF: Mechanism not established; may interfere with intracellular assembly of inflammasome complex present in neutrophils and monocytes, which mediates activation of interleukin-1β
Onset: 18-24 hr
Time to peak effect: 48-72 hr
Peak plasma concentration: 6.2-6.8 ng/mL
Protein bound: 34-44%
Vd: 5-8 L/kg
Metabolized by P-gp and CYP3A4
Metabolites: Demethylated to 2 primary metabolites and 1 minor metabolite
Half-life: 26.6-31.2 hr
Dialyzable: No (hemodialysis)
Excretion: Feces, urine (65%)
IV formulation currently not commercially available in United States
Dextrose or IV solutions with preservatives
Over 2-5 minutes, administer into tubing of NS-flowing IV line into large vein
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.